Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.31 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423058 | 0.83 | POLB (0.36) | HTR6SMARCA2SMARCA4POLBCYP3A4 | |
| SCHEMBL4425141 | 0.83 | PKM (0.42) | HTR6POLBCYP3A4MAPTCYP2C9 | |
| SCHEMBL4432215 | 0.81 | MAPT (0.41) | HTR6SMARCA2SMARCA4POLBCYP3A4 | |
| SCHEMBL4432222 | 0.81 | HTR6 (0.45) | HTR6POLBCYP3A4MAPTCYP2C9 | |
| SCHEMBL4421490 | 0.80 | ALDH1A1 (0.39) | HTR6POLBCYP3A4MAPTCYP2C9 | |
| SCHEMBL4416818 | 0.79 | HTR6 (0.39) | HTR6POLBCYP3A4MAPTCYP2C9 | |
| SCHEMBL4424954 | 0.78 | HTR6 (0.42) | HTR6POLBCYP3A4MAPTCYP2C9 | |
| SCHEMBL4427807 | 0.77 | HTR6 (0.53) | HTR6CYP3A4CYP2C19 | |
| SCHEMBL4430905 | 0.75 | MET (0.40) | HTR6CYP3A4CYP2C19 | |
| SCHEMBL4432173 | 0.75 | HTR6 (0.59) | HTR6CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544701-B2 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-06-09 | — | — | US | claimed |
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | claimed |
| US-7544701-B2 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1654258-A1 | SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005009996-A1 | SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1B | HTR6 1/4885BDKRB1 233/4885SMARCA2 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.